AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25200587 — intervention group
Group type: COMPARATOR
Intervention: EAT thickness from parasternal short-axis view in patients without CAD
Number of subjects: 153
Study 25200587 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of EAT thickness with age
Number of subjects: 153
Study 25200587 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of EAT thickness with waist circumference
Number of subjects: 153
Study 25200587 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of EAT thickness with cholesterol-HDL
Number of subjects: 153
Study 25200587 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of EAT thickness with serum adiponectin
Number of subjects: 153
Study 25200587 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of EAT thickness with severity of CAD
Number of subjects: 153
Study 22704944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine hydrochloride 0.4%
Number of subjects: 30
Study 22704944 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 20649056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg intravenously every 8 h
Number of subjects: 10
Study 20649056 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg intravenously every 12 h
Number of subjects: 10
Study 20649056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 10
Study 19146604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydradermabrasion with polyphenolic antioxidant serum (Group A)
Number of subjects: 20
Study 19146604 — intervention group
Group type: COMPARATOR
Intervention: Manual application of polyphenolic antioxidant serum (Group B)
Number of subjects: 20
Study 16934148 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics via the respiratory tract (gentamicin, polymyxins, tobramycin, ceftazidime)
Number of subjects: 1877
Study 16934148 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 1877
Study 16934148 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics via the respiratory tract
Number of subjects: 1877
Study 12564612 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness, Cough and Sputum Scale (BCSS)
Number of subjects: 629
Study 10970930 — intervention group
Group type: EXPERIMENTAL
Intervention: Home program of rehabilitation including guidance on home activities and weekly telephone calls from a psychiatric nurse.
Number of subjects: 0
Study 10970930 — intervention group
Group type: COMPARATOR
Intervention: Inpatient cognitive rehabilitation (control group).
Number of subjects: 0
Study 8970416 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol (1.5 mg/kg, intravenous)
Number of subjects: 28
Study 8970416 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 1597846 — intervention group
Group type: EXPERIMENTAL
Intervention: DTZ SR/HCTZ (120/12.5 mg)
Number of subjects: 298
Study 1597846 — intervention group
Group type: EXPERIMENTAL
Intervention: DTZ SR/HCTZ (60/6.25 mg)
Number of subjects: 298
Study 1597846 — intervention group
Group type: EXPERIMENTAL
Intervention: DTZ SR/HCTZ (90/6.25 mg)
Number of subjects: 298
Study 1597846 — intervention group
Group type: COMPARATOR
Intervention: HCTZ (6.25, 6.25, 12.5 mg twice daily)
Number of subjects: 298
Study 1597846 — intervention group
Group type: COMPARATOR
Intervention: DTZ SR (60, 90, 120 mg twice daily)
Number of subjects: 298
Study 1597846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 4093916 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 valent pneumococcal vaccine
Number of subjects: 77
Study 4093916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 31210018 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consultations
Number of subjects: 102
Study 31210018 — intervention group
Group type: COMPARATOR
Intervention: Traditional consultations
Number of subjects: 102
Study 29153273 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (8 sessions)
Number of subjects: 8
Study 26869076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Suicide Prevention (CBSP) therapy
Number of subjects: 60
Study 26869076 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study 25257667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography screening for breast cancer
Number of subjects: 376
Study 22699129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg bolus followed by continuous infusion of 1.5 mg/kg/h, stopped 1 hour after skin closure
Number of subjects: 36
Study 22699129 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 36
Study 20585115 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-RIF for 8 weeks
Number of subjects: 0
Study 20585115 — intervention group
Group type: COMPARATOR
Intervention: SM-RIF for 4 weeks followed by RIF-CLA for 4 weeks
Number of subjects: 0
Study 17909305 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy for 12 weeks followed by medroxyprogesterone acetate for 2 weeks
Number of subjects: 11
Study 17909305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15516532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (3 x 40 mg/day for 6 days)
Number of subjects: 12
Study 15516532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11801428 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial electrical stimulation with a train of 5 stimuli of 50 micros duration, interstimulus interval of 5 ms, and intensity of 500 V
Number of subjects: 100
Study 11801428 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural recordings of corticospinal volleys
Number of subjects: 100
Study 11801428 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstimulus interval of 5 ms
Number of subjects: 100
Study 11801428 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticospinal volleys
Number of subjects: 100
Study 9459371 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid/d (high-C diet)
Number of subjects: 36
Study 9459371 — intervention group
Group type: COMPARATOR
Intervention: Low-C diet (50 mg ascorbic acid/d)
Number of subjects: 36
Study 7629982 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1.0 g as a single oral dose)
Number of subjects: 452
Study 7629982 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg taken orally twice daily for 7 days)
Number of subjects: 452
Study 7629982 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (for those infected with C trachomatis)
Number of subjects: 452
Study 7629982 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (for those infected with C trachomatis)
Number of subjects: 452
Study 7629982 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (for those infected with U urealyticum)
Number of subjects: 452
Study 7629982 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (for those infected with U urealyticum)
Number of subjects: 452
Study 7629982 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 452
Study 7629982 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 452
Study 2775615 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (50 mg) administered intravenously
Number of subjects: 0
Study 2775615 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (250 mg) administered orally
Number of subjects: 0
Study 2775615 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (50 mg) administered intravenously in the presence of carbidopa
Number of subjects: 0
Study 408312 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 51
Study 408312 — intervention group
Group type: COMPARATOR
Intervention: Air (Control)
Number of subjects: 51
Study 30066465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone group (20 mL bupivacaine 0.5% + 2 mL dexamethasone 8 mg)
Number of subjects: 60
Study 30066465 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 mL bupivacaine 0.5% + 2 mL normal saline)
Number of subjects: 60
Study 30066465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 60
Study 30066465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 29157469 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-individualised homeopathy
Number of subjects: 26
Study 24715230 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival and/or intrastromal injections of 5 mg/0.2 ml Bevacizumab (3 injections)
Number of subjects: 27
Study 24715230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Bevacizumab injections)
Number of subjects: 27
Study 23157561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intervention (HI) group adopting Mediterranean diet
Number of subjects: 38
Study 23157561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intervention (LI) group adopting Mediterranean diet
Number of subjects: 38
Study 23157561 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 21777886 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents with prolonged drug release (ZES-SR)
Number of subjects: 43
Study 21777886 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents with faster kinetics (ZES-FR)
Number of subjects: 43
Study 21777886 — intervention group
Group type: EXPERIMENTAL
Intervention: ZES-SR
Number of subjects: 43
Study 21777886 — intervention group
Group type: COMPARATOR
Intervention: ZES-FR
Number of subjects: 43
Study 19716142 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adiponectin
Number of subjects: 256
Study 19716142 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma leptin
Number of subjects: 256
Study 16454147 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnolia officinalis and Phellodendron amurense extracts (250 mg capsules, 3 times a day for 6 weeks)
Number of subjects: 28
Study 16454147 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (identical to treatment)
Number of subjects: 28
Study 16454147 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnolia officinalis and Phellodendron amurense extracts
Number of subjects: 28
Study 16454147 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 28
Study 16454147 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment and placebo groups
Number of subjects: 28
Study 12826696 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) gel
Number of subjects: 0
Study 12826696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) gel
Number of subjects: 0
Study 10808696 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hormonal replacement therapy (HRT) with conjugated equine estrogen 0.625 mg/day and medroxyprogesterone acetate 2.5 mg/day for 21.3 +/- 9.5 months.
Number of subjects: 38
Study 10808696 — intervention group
Group type: COMPARATOR
Intervention: No hormonal replacement therapy (Control group).
Number of subjects: 38
Study 8625757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20
Study 8625757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1599726 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-visit intervention group (risk assessment, support, cessation date setting, self-help literature, nicotine gum prescription)
Number of subjects: 647
Study 1599726 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-visit intervention group with additional four supportive follow-up visits
Number of subjects: 647
Study 1599726 — intervention group
Group type: COMPARATOR
Intervention: Two-visit intervention group (brief intervention)
Number of subjects: 647
Study 1599726 — intervention group
Group type: COMPARATOR
Intervention: Two-visit intervention group with follow-up visits
Number of subjects: 647
Study 4060998 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural nicomorphine post-operatively
Number of subjects: 163
Study 4060998 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular opiates post-operatively
Number of subjects: 163
Study 4060998 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural group
Number of subjects: 163
Study 4060998 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular group
Number of subjects: 163
Study 27881624 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy self-help intervention
Number of subjects: 0
Study 27881624 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30579505 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 16800
Study 30579505 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 16800
Study 30579505 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate multi-morbidity
Number of subjects: 16800
Study 30579505 — intervention group
Group type: EXPERIMENTAL
Intervention: High multi-morbidity
Number of subjects: 16800
Study 30579505 — intervention group
Group type: COMPARATOR
Intervention: No multi-morbidity
Number of subjects: 16800
Study 28545041 — intervention group
Group type: EXPERIMENTAL
Intervention: Early measles vaccine (MV) at 18 weeks of age
Number of subjects: 512
Study 28545041 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early MV)
Number of subjects: 512
Study 25457820 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis (DO)
Number of subjects: 66
Study 25457820 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Sagittal Split Osteotomy (BSSO)
Number of subjects: 66
Study 23819119 — intervention group
Group type: EXPERIMENTAL
Intervention: M group with reflective markers
Number of subjects: 50
Study 23819119 — intervention group
Group type: COMPARATOR
Intervention: NM group without reflective markers
Number of subjects: 50
Study 22308653 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal ointment containing cinnamon, ginger, mastic (Saghez) and sesame oil applied twice a day for six weeks
Number of subjects: 92
Study 22308653 — intervention group
Group type: COMPARATOR
Intervention: Salicylate ointment applied twice a day for six weeks
Number of subjects: 92
Study 20011859 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 100 microg
Number of subjects: 60
Study 20011859 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 200 microg
Number of subjects: 60
Study 20011859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16495243 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin at 10 mg/kg intravenously every 24 h
Number of subjects: 195
Study 16495243 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (antistaphylococcal penicillin at 2 g q6h or vancomycin at 1 g q12h)
Number of subjects: 195
Study 15535882 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (patient education and exercise therapy)
Number of subjects: 0
Study 15535882 — intervention group
Group type: COMPARATOR
Intervention: General practitioners management only (control)
Number of subjects: 0
Study 11288212 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 40
Study 9209606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (2.5 +/- 0.9 mg.kg-1.h-1) and midazolam (0.15 +/- 0.07 mg.kg-1.h-1)
Number of subjects: 25
Study 9209606 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil/midazolam
Number of subjects: 25
Study 7965152 — intervention group
Group type: EXPERIMENTAL
Intervention: BMIPP uptake
Number of subjects: 22
Study 7965152 — intervention group
Group type: EXPERIMENTAL
Intervention: BMIPP and MIBI uptake
Number of subjects: 22
Study 7965152 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched defects
Number of subjects: 22
Study 7965152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatching
Number of subjects: 22
Study 3331041 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg b.i.d. (suspended in saline)
Number of subjects: 346
Study 3331041 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg t.i.d. (suspended in saline)
Number of subjects: 346
Study 3331041 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg b.i.d. (suspended in 1% lidocaine)
Number of subjects: 346
Study 3331041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two regimens
Number of subjects: 346
Study 3331041 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 346
Study 28639086 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD1
Number of subjects: 32
Study 28639086 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD2
Number of subjects: 32
Study 28639086 — intervention group
Group type: COMPARATOR
Intervention: Pelli‐Robson (printed version)
Number of subjects: 32
Study 27287751 — intervention group
Group type: EXPERIMENTAL
Intervention: Rethink your Smoking program (RSP)
Number of subjects: 199
Study 27287751 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Intervention (MI) program
Number of subjects: 199
Study 27287751 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 199
Study 24944058 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG/IMP+ (monosodium glutamate and inosine 5'-monophosphate added to soup)
Number of subjects: 26
Study 24944058 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate and -protein soup
Number of subjects: 26
Study 24944058 — intervention group
Group type: COMPARATOR
Intervention: MSG/IMP- (soup without added monosodium glutamate and inosine 5'-monophosphate)
Number of subjects: 26
Study 24944058 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG/IMP+
Number of subjects: 26
Study 23093347 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (28.2 or 56.5 μg injection)
Number of subjects: 30
Study 23093347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22136422 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (109 viable bacteria per day for 21 days)
Number of subjects: 52
Study 22136422 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 52
Study 22136422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 52
Study 17607055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pies Sanos intervention
Number of subjects: 135
Study 17607055 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 17607055 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison between groups
Number of subjects: 135
Study 17607055 — intervention group
Group type: COMPARATOR
Intervention: Baseline diabetes self-efficacy
Number of subjects: 135
Study 17257460 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100-400 mg, administered once daily or as a divided dose)
Number of subjects: 220
Study 12603363 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 178
Study 12603363 — intervention group
Group type: COMPARATOR
Intervention: Psoriasis patients
Number of subjects: 178
Study 12603363 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 178
Study 10840295 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus sclerotherapy
Number of subjects: 86
Study 10840295 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 86
Study 9589355 — intervention group
Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol (I3C) 300 mg and 400 mg high-dose (HD)
Number of subjects: 60
Study 9589355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 60
Study 9589355 — intervention group
Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol (I3C) 50 mg, 100 mg, 200 mg low-dose (LD)
Number of subjects: 60
Study 8246267 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG serum fractions from CF patients
Number of subjects: 21
Study 8246267 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG serum fractions from CF patients with strong inhibition
Number of subjects: 21
Study 8246267 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG subclass response to OMPs
Number of subjects: 21
Study 8246267 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 3113800 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms q.i.d
Number of subjects: 0
Study 3113800 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 50 micrograms q.i.d
Number of subjects: 0
Study 3113800 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 200 micrograms q.i.d
Number of subjects: 0
Study 3113800 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg q.i.d
Number of subjects: 0
Study 3113800 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (another PGE2 analog)
Number of subjects: 0
Study 30577546 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban children
Number of subjects: 2020
Study 30577546 — intervention group
Group type: COMPARATOR
Intervention: Rural children
Number of subjects: 2020
Study 30577546 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall children
Number of subjects: 2020
Study 30577546 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dietary intake
Number of subjects: 2020
Study 26876722 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up by study nurses with continuous contact, counseling on healthy living, and titration of medicines for blood pressure and blood lipids.
Number of subjects: 661
Study 26876722 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up by a general practitioner.
Number of subjects: 661
Study 24385282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotoxic group (n=77)
Number of subjects: 226
Study 24385282 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=149)
Number of subjects: 226
Study 15735366 — intervention group
Group type: EXPERIMENTAL
Intervention: High-genistein isoflavone extract (HGI, 150 mg/day)
Number of subjects: 30
Study 15735366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12797715 — intervention group
Group type: EXPERIMENTAL
Intervention: King's Health Questionnaire (KHQ) administered at baseline and 12 weeks post-treatment
Number of subjects: 1284